Yousif Capital Management LLC Boosts Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Yousif Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,816 shares of the company’s stock after purchasing an additional 2,830 shares during the period. Yousif Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $986,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Golden State Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at about $39,000. New Age Alpha Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at about $43,000. Sound Income Strategies LLC raised its position in shares of Teva Pharmaceutical Industries by 3,715.8% in the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after buying an additional 2,824 shares during the last quarter. Banque Cantonale Vaudoise acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at about $74,000. Finally, Brooklyn Investment Group raised its position in shares of Teva Pharmaceutical Industries by 403.4% in the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock valued at $77,000 after buying an additional 4,014 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $19.01 on Wednesday. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. The stock has a market cap of $21.80 billion, a P/E ratio of -118.78, a PEG ratio of 1.07 and a beta of 0.71. The company has a 50-day moving average price of $19.00 and a 200 day moving average price of $17.18. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. Teva Pharmaceutical Industries’s revenue was up .3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares of the company’s stock, valued at $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an “overweight” rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $25.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.